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Multiplexed CRISPR technologies for gene editing
and transcriptional regulation
Nicholas S. McCarty 1, Alicia E. Graham2,3, Lucie Studená 2,3 &
Rodrigo Ledesma-Amaro 2✉
Multiplexed CRISPR technologies, in which numerous gRNAs or Cas enzymes are expressed
at once, have facilitated powerful biological engineering applications, vastly enhancing the
scope and efficiencies of genetic editing and transcriptional regulation. In this review, we
discuss multiplexed CRISPR technologies and describe methods for the assembly, expression
and processing of synthetic guide RNA arrays in vivo. Applications that benefit from
multiplexed CRISPR technologies, including cellular recorders, genetic circuits, biosensors,
combinatorial genetic perturbations, large-scale genome engineering and the rewiring of
metabolic pathways, are highlighted. We also offer a glimpse of emerging challenges and
emphasize experimental considerations for future studies.
Most archaea and about half of bacteria carry the genes necessary for CRISPR–Casadaptive immunity, which provides a memory of prior infections by encoding shortDNA sequences into CRISPR (clustered regularly interspaced short palindromic
repeats) loci within their genome. These prior infections are stored as spacer sequences, each of
which is flanked by repeat sequences. Spacer repeats are transcribed into pre-crRNA (CRISPR
RNAs), which are then processed into functional crRNAs1. Native CRISPR–Cas systems are
inherently multiplexed; organisms can encode one or several CRISPR arrays and express
numerous Cas (CRISPR-associated) proteins that facilitate the acquisition of new spacers and
process the CRISPR arrays2.
Over the last few years, thousands of studies have employed CRISPR–Cas technologies to edit,
or transcriptionally regulate, individual genetic loci based on their sequence complementarity
with designed guide RNAs (gRNAs). Despite the general utility of CRISPR–Cas technologies, the
use of an individual gRNA limits efficiencies and biotechnological applications. Therefore, there
is now a growing trend in studies that move away from mono-guide approaches, and instead use
multiplexed strategies for multi-locus editing or transcriptional regulation. While only four
PubMed papers mentioned “multiplex” and “CRISPR” in 2013, 81 such papers were published in
2018. CRISPR systems underpinning bacterial adaptive immunity function thanks to an intricate
dance between CRISPR arrays and multiple Cas enzymes; the core of this review advocates for a
return to this “natural state” and emphasizes the advantages of expressing multiple Cas proteins
or gRNAs simultaneously in vivo to edit or transcriptionally regulate numerous genetic loci in
parallel.
In this review, we highlight strategies to create and process synthetic gRNA arrays in
a multitude of organisms, emphasize the utility of inducible and orthogonal CRISPR–Cas
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technologies, and discuss the plethora of applications made
possible by parallel targeting of genes in vivo, including biosen-
sing, large-scale genome engineering, the construction of logic
circuits, and metabolic engineering. We also argue for an
enhanced focus on rigorous, quantitative experiments to fully
validate and study gRNA functions in vivo, and describe the suite
of computational tools available to design gRNAs. Finally, we
conclude with outstanding challenges and future scientific
directions ripe for innovation in the CRISPR multiplexing field.
CRISPR for gene editing and transcriptional regulation
While many Cas proteins have been discovered, Cas9 and Cas12a
(also known as Cpf1), which are RNA-guided endonucleases that
cleave target DNA, are the most commonly used for genetic
editing and transcriptional regulation3. Cas9 and Cas12a are
remarkably simple to program and can be directed to DNA tar-
gets via Watson-Crick base pairing between the genetic target and
gRNA. In native CRISPR systems, gRNAs for Cas9 are comprised
of a crRNA:tracrRNA complex, which can be fused together via
genetic engineering to form a sgRNA (single gRNA), while those
for Cas12a consist solely of a crRNA3,4. To avoid confusion
throughout this review, we use the term ‘gRNA’ to represent
all CRISPR gRNA formats4. After forming a ribonucleoprotein
complex with a gRNA, Cas9 and Cas12a perform a double-strand
break adjacent to a protospacer adjacent motif (PAM), a sequence
that is required for target recognition and varies between endo-
nucleases4. This double-strand break enables genome editing
applications.
By mutating specific amino acids in Cas9 and Cas12a, DNA
cleavage activity in these enzymes is abolished, thus converting
them into nuclease-null mutants, denoted as dCas9 and
dCas12a5. Fusion of dCas enzymes to effector domains enables
efficient transcriptional regulation, including CRISPR-mediated
inhibition (CRISPRi) and activation (CRISPRa)5,6. Mechan-
istically, dCas enzymes repress transcription by preventing
the binding of RNA polymerase or, if targeted to open reading
frames, by interfering with transcription elongation5,7.
In eukaryotes, dCas is typically fused to an effector domain to
enhance repression by recruiting chromatin remodeling pro-
teins while, in bacteria, dCas enzymes alone are usually suffi-
cient to repress gene expression by physically blocking RNA
polymerase5,6,8. Similarly, effector domains for CRISPRa work
by recruiting RNA polymerase or by recruiting endogenous
transcriptional activators6,7,9–13.
Both CRISPR-based gene editing and transcriptional regulation
benefit from multiplexing (Fig. 1). By producing multiple gRNAs
and a Cas protein in vivo, researchers can build layered genetic
circuits that control cellular behavior or modulate metabolic
pathways with the simultaneous editing, activation, and down-
regulation of multiple target genes14–17. For gene editing, CRIS-
PRa and CRISPRi, the targeting of multiple gRNAs to a single
genetic locus also enhances the efficiency of DNA editing and
transcriptional control18–20.
Importantly, many methods to express and process multi-
plexed gRNAs in vivo are based on crRNA-processing mechan-
isms found in native CRISPR systems. To process CRISPR arrays,
some native systems rely on the nuclease itself (e.g., Cas12a and
Cas13a), some rely on accessory proteins that are part of the final
effector complex (e.g., Cas6/Csy4 as part of Cascade), and others
rely upon a combination of tracrRNA (transactivating crRNA)
and RNase III (e.g., Cas9, Cas12b, and Cas12c)21.
Transcription and processing of gRNA arrays
While a simple approach to target multiple genetic loci at once
in vivo is to simply transfect cells with preformed ribonucleoprotein
complexes, many applications (discussed in the following sections)
demand sustained functionality of CRISPR–Cas over time. For-
tunately, in recent years, many strategies to genetically encode,
transcribe and process large numbers of gRNAs in vivo have been
developed.
There are three main “genetic architectures” for multiplexed
gRNA expression. In both eukaryotes and bacteria, multiple
gRNAs can be expressed by encoding each under the control of
an individual promoter (typically Pol III U6 promoters in
mammalian cells and Pol III tRNA promoters in yeast and plants)
and terminator (Fig. 2a). Pol III promoters are high fidelity, but
have a lower processivity than Pol II promoters22. Both Pol II and
Pol III promoters have been used to express gRNAs for
CRISPR–Cas studies, but Pol II promoters are easily tuned and
often inducible.
In the second type of genetic architecture for multiplexed gRNA
expression, gRNAs are encoded and processed by mechanisms
derived from native CRISPR–Cas systems. For example, arrays of
gRNAs can be processed by RNase III in a tracrRNA-dependent
manner, which is the same mechanism by which crRNAs are
processed in Type II CRISPR systems (Fig. 2b)21. This strategy
enabled at least four genetic loci to be edited simultaneously in
Saccharomyces cerevisiae, Escherichia coli, and cell-free extract23.
The intrinsic crRNA-processing capabilities of Cas12a have also
been leveraged to process a large number of gRNAs from a single
RNA transcript, both constitutively and inducibly (Fig. 2c)23–25.
Cas12a cleaves pre-crRNA via recognition of hairpin structures
formed within the spacer repeats, producing mature crRNAs26.
Editing
CRISPRiCRISPRa
Activation Repression
Multiplexed CRISPR
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Fig. 1 Basic overview of multiplexed CRISPR–Cas technologies.
Multiplexed CRISPR–Cas can be implemented by simultaneously expressing
multiple gRNAs at once. By adding orthologous Cas enzymes, gene editing,
transcriptional activation (CRISPRa) and transcriptional repression
(CRISPRi) can be performed in tandem at numerous locations in the
genome. Cas enzymes are represented by the shaded green shape, while
green and red cylinders attached to the Cas enzymes represent activation
and repression domains, respectively. Editing requires that a Cas enzyme
cleave dsDNA, which is repaired by error-prone, non-homologous end
joining. Transcriptional regulation occurs by targeting nuclease-null Cas
enzymes to specific regions up- or downstream of a transcription start site
to either occlude RNA polymerase binding sites, or to recruit transcription
factors (via fused effector domains) for activation or repression of the
target gene.
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Tandem expression of Cas12a and an array of crRNAs from a
single Pol II promoter in human cells enabled five target genes to
be cleaved, and an additional ten target genes to be tran-
scriptionally regulated, concurrently24. Multiplexed targeting via
Cas12a has also been demonstrated in plants, yeast, and bac-
teria27–29. In addition, spacers for both Cas9 and Cas12a can
be transcribed and processed from a single array simultaneously,
with the spacers for Cas9 processed by endogenous tracrRNA-
dependent RNase III23.
A third architecture for multiplexed gRNA expression is to
produce a single transcript encoding multiple gRNAs, each
separated by RNA cleavage sequences. This enhances the mod-
ularity and stoichiometry of gRNAs in vivo for CRISPR multi-
plexing, but demands that additional processing mechanisms are
implemented to produce functional gRNAs from a single array24.
Common strategies to accomplish this include co-expression
of RNA processing enzymes, such as Csy4, or by flanking each
gRNA with self-cleaving ribozymes or tRNAs.
Multiplexing can be achieved from long RNA transcripts by
flanking each gRNA with the virus-derived, cis-acting Hammer-
head and hepatitis delta virus ribozymes. This strategy is amen-
able to both Pol II and Pol III-mediated transcription and has
been demonstrated in multiple organisms (Fig. 2d)30–32.
gRNA arrays can also be expressed from Pol II or Pol III
promoters and excised by Cas family endonucleases, such as
Csy4, which processes pre-crRNAs in some native CRISPR sys-
tems (Fig. 2e)33. Csy4 recognizes a 28-nt stem–loop sequence in
RNA transcripts and cleaves after the 20th nucleotide33. By
flanking each gRNA in an array with the Csy4 recognition
sequence, multiple gRNAs can be expressed and processed from a
single promoter in mammalian cells, yeast, and bacteria30,34,35.
Our group previously expressed and processed 12 sgRNAs in S.
cerevisiae from a single Pol II promoter with co-expression of
Csy420. Though Csy4-mediated processing of gRNA arrays
enables a large number of gRNAs to be processed from a single
RNA transcript, co-expression of Csy4 is sometimes undesirable
because of cytotoxicity at high concentrations30.
Numerous studies have also exploited endogenous tRNA-
processing machinery to process arrays of gRNAs flanked by
77-nt long pre-tRNA genes36–38. Processing of pre-tRNAs is
mediated by ribonucleases P and Z, which cleave near the 5′ and
3′ ends, respectively, of each pre-tRNA (Fig. 2f). RNase P and Z
are found in all domains of life and thus enable numerous gRNAs
to be processed from tRNA–gRNA arrays in many organisms.
tRNA–gRNA arrays can also be encoded in eukaryotic introns
and processed by the spliceosome complex, an approach that
enabled both an endonuclease (encoded in an exon) and multiple
gRNAs to be expressed from a single Pol II promoter in rice
protoplasts39.
Remarkable progress has been made in harnessing biomolecular
mechanisms to produce and process increasingly long gRNA
arrays. However, it is still often technically challenging to create
these synthetic arrays due, in part, to the presence of highly
repetitive DNA sequences.
Methods for assembly of highly repetitive gRNA arrays
Most methods to assemble gRNA arrays do so via derivatives
of popular cloning methods, such as Gibson or Golden Gate
Assembly, since the repetitive sequences within gRNA arrays
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Fig. 2 General strategies to express multiple gRNAs in vivo. The expression and processing of multiplexed gRNAs typically occur via three distinct
mechanisms; arrayed sgRNA expression constructs, in which each construct contains a promoter, sgRNA, and terminator (green header), CRISPR arrays,
wherein each gRNA is processed via a native CRISPR processing mechanism (blue headers), or synthetic gRNA arrays, in which each gRNA is flanked by
RNA cleavage sites (red headers). a A common method to express numerous gRNAs in vivo is to express each gRNA from an individual promoter. b A
strategy to process crRNA arrays, based on Type II CRISPR systems, is to flank each crRNA with a direct repeat, a repetitive sequence required for
processing of pre-crRNA. tracrRNA is expressed separately. RNase III is an endogenous enzyme that removes these direct repeats in a tracrRNA-
dependent manner. c Cas12a and Cas13a can process crRNA arrays and remove direct repeats, even in the absence of tracrRNA. d An engineering
approach to process arrays involves flanking each gRNA with self-cleaving sequences, such as Hammerhead or HDV ribozymes. Arrays of this form have
been expressed from both Pol II and Pol III promoters. e Csy4 is an enzyme that recognizes a 28-nt stem–loop sequence in RNA and cuts after the 20th
nucleotide. Exogenous co-expression of Csy4 can be used to process gRNA arrays, provided that each gRNA is flanked by its recognition sequence. f gRNA
arrays flanked by tRNAs can be transcribed (either by Pol II or Pol III promoters) and processed by endogenous RNase P and RNase Z, which cut the 5′ and
3′ ends, respectively, of pre-tRNAs, to produce functional gRNAs. For each sgRNA, the portion in gray is derived from the tracrRNA, while the portion in
blue indicates the 20-nt spacer sequence.
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often make pure chemical synthesis unviable40,41. Assembly
approaches for building synthetic gRNA arrays can be further
divided into those purpose built for a specific organism, and more
general strategies.
Many systems to build synthetic arrays utilize plasmid-based
cloning toolkits in which annealed oligonucleotides encoding
gRNAs are ligated into digested plasmids with predesigned Type
IIs restriction sites. Golden Gate, Gibson Assembly, or recombi-
nation is then used to join multiple gRNA-expressing entry
vectors together into a digested vector, which contains a promoter
and terminator for expression of the assembled array (Fig. 3a).
Conversely, some methods use annealed oligos containing com-
plementary overhangs that specify the order of each gRNA “unit”,
thus enabling their direct ligation into a digested vector23. Array
assembly methods of this type are rapid and easy to use, and have
been reported for many organisms34,38,42–45.
Other options to produce gRNA arrays rely on a smaller set of
plasmid-based parts to produce gRNAs and clone them into
arrays (Fig. 3b). In these "lightweight" systems, one plasmid is
typically used as a template to produce PCR amplicons, each of
which is a gRNA “unit” consisting of 5′ and 3′ Type IIs restriction
sites, a full gRNA, and a direct repeat, Csy4 recognition site,
ribozyme, or other repetitive sequence. Units are digested and
ligated into a destination vector, thus completing a functional
array for in vivo gene expression20,46. We previously used this
approach to build an array with 12 gRNAs, each flanked by Csy4
recognition sites, using two plasmids in just two days20. A slight
variation of the same strategy also enabled the assembly of an
array with 24 gRNAs, each flanked by a Csy4 recognition site47.
gRNA arrays flanked by direct repeats can also be constructed
by ligating together synthesized DNA fragments, each containing
2–6 gRNAs (Fig. 3c). This general strategy of “synthesis and
ligation” enabled the assembly of a single transcript that encodes
25 gRNAs for multiplexing in mammalian cells23,24. Recent
efforts have also sought to reduce the number of repetitive
sequences within gRNAs themselves, thus enabling the synthesis
of DNA fragments encoding extra long gRNA arrays48. The
handle of Cas9 sgRNAs (the portion that binds Cas9) is 42-nt in
length and makes direct synthesis challenging. To circumvent this
limitation, a recent study designed and validated a library of
orthogonal, nonrepetitive Cas9 handles, promoters and termi-
nators for E. coli, thus enabling up to 22 sgRNAs—each expressed
from an individual promoter and terminator—to be synthesized
in 3 kb chunks and ligated together48.
As synthetic gRNA arrays grow in length, however, it is
important to consider the strategies employed to process the
RNA transcripts. With long arrays, Pol III-based methods,
including tRNA-mediated processing, quickly become unfea-
sible due to limitations on processivity (only up to eight gRNAs
have been produced from this type of array)38. The best stra-
tegies to achieve higher multiplexing of gRNAs thus far seem to
rely either on co-expression of Csy4 or on the self-processing
and targeting capabilities of Cas12a20,24. Both of these strategies
are used by native systems to produce and cleave CRISPR
arrays, lending credence to their ability to efficiently process
very long, repetitive RNA transcripts3,33,49.
Efficiencies of multiplexed gene editing, CRISPRi, and
CRISPRa
Cas enzymes can either be programmed to target many genes at
once, or multiple gRNAs can be directed to a single genetic locus to
enhance the efficiency of editing or transcriptional regulation
(Table 1). A recent study in mammalian cells, for instance,
demonstrated that the efficiency of Cas12a-mediated editing with
10 gRNAs directed to a single locus is about 60%, whereas indivi-
dual gRNAs had much lower efficiencies (ranging from 2 to 17%)24.
Oligo assembly
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Fig. 3 Assembly methods for synthetic gRNA arrays. a Oligo-based assembly methods are frequently used to assemble arrays. This approach works by
annealing oligonucleotides that encode each gRNA unit, and then ligating these units into digested vectors which already contain predesigned Type IIs
restriction sites and 4-nt overhangs. Each gRNA-containing entry vector is then cloned into a destination vector, which contains a promoter and terminator
to express the assembled array. Conversely, oligos can be annealed that already contain complementary overhangs for direct ligation into a digested vector
(shown on the right side). b A second strategy, referred to as PCRs and Golden Gate, utilizes a single vector with a repetitive “processing” sequence (either
direct repeats, tRNA, ribozymes, or a Csy4 recognition site) as a template for PCR. Primer extensions add the desired spacer sequence and Type IIs
restriction sites with specified, 4-nt overhangs. Digestion of each PCR amplicon, followed by Golden Gate assembly into a predigested destination vector, is
used to assemble the final array. This strategy is both inexpensive and adaptable but requires multiple steps for cloning. c A more versatile, but expensive,
strategy uses direct synthesis and ligation to build arrays. Briefly, multiple gRNA units are synthesized in tandem, and the ends of each synthesized piece of
DNA contain overhangs for Gibson Assembly, specified Type IIs restriction sites for Golden Gate, or some other sequence to mediate DNA joining. In some
cases, DNA synthesis can be directly used to directly build a full gRNA array.
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In most cases, however, it is desirable to direct gRNAs to
multiple genetic loci at once. Targeting of Cas9 to ten different
genes in human cells simultaneously has demonstrated that
gRNAs expressed from arrays mediate genetic disruptions at
efficiencies similar to gRNAs tested at each locus individually34.
In rice protoplasts, four chromosomal deletions (eight total loci)
have been performed simultaneously with 4–45% efficiency36. In
S. cerevisiae, gRNA arrays have been used to implement up to
eight simultaneous gene disruptions at once, with 86.7% of cells
having all eight disruptions38. At least four genes have also
been disrupted concurrently in E. coli with efficiencies greater
than 30%50.
Multiplexed gRNAs are not only beneficial for gene editing,
though. gRNA arrays are increasingly being utilized to tune the
transcription of multiple genetic loci in tandem. In human cells,
for example, ten genes have been transcriptionally repressed at
once with dCas12a-based CRISPRi, with efficiencies ranging from
40 to 80%24. Our lab has previously expressed up to 12 sgRNAs
from a single promoter in S. cerevisiae, targeting 4 sgRNAs to
three distinct genes in parallel, with transcriptional repression
efficiencies between 81 and 95%20. In E. coli, four loci have also
been repressed simultaneously by dCas12a by about 50-fold
each51.
CRISPRa applications also benefit from multiplexing. In
human cells, dCas12a-based activators with three gRNAs target-
ing a single gene increased gene activation by 9- to 40-fold
relative to single gRNAs while, with dCas9-VPR (a tripartite
activator comprised of VP64–p65–Rta), four sgRNAs targeting a
Table 1 Assembly methods and efficiencies for multiplexed CRISPR systems.
CRISPR
assembly system
Maximum
sgRNAs
assembled
Efficiency of edits (E)
or transcriptional
repression (R) or
activation (A) from a
single construct
Promoters used Method of
processing
Assembly method Validated
organisms
Endonucleases tested Reference
McCarty et al. 12 (R) 3 targets, 81-95% Single Pol II Csy4 cleavage Golden Gate S. cerevisiae Cas9 20
GTR-CRISPR 8 (E) 8 targets, 87% Two Pol III
Promoters
tRNA Processing Golden Gate S. cerevisiae Cas9 38
CRATES 7 (E) Plasmid-clearance
assays, 4 targets,
>100-fold
Single
Constitutive
Promoter
Endogenous
tracrRNA/RNase III
for Cas9,
Endogenous
nuclease processing
for Cas12a/Cas13a
crRNA Trimming,
Golden Gate
S. cerevisiae,
E. coli, cell-
free
Cas9, Cas12a, Cas13a 23
Mans/Rossum 6 (E) 6 targets, 65% Multiple Pol III Individual cassettes Gibson Assembly S. cerevisiae Cas9 109
Lightning GTR-
CRISPR
6 (E) 4 targets with
96%, 6 targets
with 60%
Two Pol III
Promoters
tRNA Processing Golden Gate S. cerevisiae Cas9 38
HI-CRISPR 3 (E) 3 targets, 100% Single Pol III Endogenous
tracrRNA/RNase III
Golden Gate S. cerevisiae Cas9 110
CasEMBLR 5 (E) 1-5 targets, 50-
100%
Multiple Pol III Individual cassettes Recombination in
vivo
S. cerevisiae Cas9 111
CRISPR-LEGO 4 (R) 2 genes, >90% Single Pol II tRNA Processing Golden Gate S. cerevisiae Cas9 45
Lian et al. 3 (E) >90%, 1 gene; (R)
10-fold, 1 gene; (A) 5-
fold, 1 gene
Single Pol II Csy4 cleavage Golden Gate S. cerevisiae Cas9, Cas12a 15
CAM 3 (E) 3 targets, 64% Multiple Pol III Individual cassettes Recombination
in vivo
S. cerevisiae Cas9 112
CRISPRm 3 (E) 1-3 targets, 81-
100%
Single Pol III Self-cleaving
ribozymes
Digestion +
Ligation Cloning
S. cerevisiae Cas9 113
Generoso et al. 2 (E) 3 targets, >90% Multiple Pol IIII Individual cassettes Gibson Assembly S. cerevisiae Cas9 114
ELSAs 22 (R) 9 genes, 3-fold to
162-fold
Individual
Promoter for
each gRNA
Individual cassettes DNA Synthesis,
Gibson Assembly
E. coli Cas9 48
CRISPathBrick 5 (R) 2 targets on 1
gene, 90-99%
Single
Constitutive
Promoter
Endogenous
tracrRNA/RNase III
Golden Gate E. coli Cas9 43
Vad-Nielsen et al. 30 (R) 5 genes, 30-60% Multiple Pol III Individual cassettes Golden Gate HEK293T Cas9 44
Campa,
Weisbach et al.
25 (R) 10 genes, 35-
90%, (E) 5 genes,
7-17% indels
Single Pol II Cas12a-mediated
processing
Gene Synthesis
and Golden Gate
HEK293T Cas12a 24
ASAP 10 (E) 10 genes, 50% Multiple Pol III Individual cassettes Golden Gate HEK293T Cas9 115
Kurata et al. 10 (E) 10 targets, 0-
18% indels
Single Pol III Csy4 cleavage Golden Gate HEK293T Cas9 34
Sakuma et al. 7 (E) 7 genes, 4.3-
36.7%
Multiple Pol III Individual cassettes Golden Gate HEK293T Cas9 116
MuLE 4 (E) 3 genes, 50%
edited at all 6 alleles
Multiple Pol III Individual cassettes Gateway (attL-
attR
Recombination)
HEK293T Cas9 117
Kabadi et al. 4 (E) 4 genes, 17.9-
33.3% in HEK293T;
(E) 4 genes, 4.8-
18.4% in fibroblasts
Multiple Pol III Individual cassettes Golden Gate HEK293T,
Fibroblasts
Cas9 118
STAgR 8 (A) 3 targets, 6-fold
to 380-fold activation
Multiple Pol III Individual cassettes Gibson Assembly HeLa Cas9 46
Yin et al. 5 (E) 2 genes, 15-
30% indels
Multiple Pol III Individual cassettes Golden Gate Zebrafish Cas9 119
Ma et al. Plants 8 (E) Multiple plasmids,
46 targets, average
85.4% mutation
Multiple Pol III Individual cassettes Golden Gate
or Gibson
Rice,
Arabidopsis
Cas9 120
Xie et al. 8 (E) 5 genes, 50% Single Pol III tRNA Processing Golden Gate Rice Cas9 36
Xing et al. 4 (E) 2 genes, 67% Multiple Pol III Individual cassettes Golden Gate
or Gibson
Maize,
Arabidopsis
Cas9 42
#This table is an updated, expanded version based upon a prior research article38. It is ordered by organism from largest to smallest number of gRNAs expressed (E, editing; A, activation; R, repression).
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single gene enhanced gene activation by more than 1000-
fold11,18,19,52. Three to sevenfold activation of three genes in
rice protoplasts has also been achieved, but required a modified
dCas9-fusion protein53.
To ensure efficient editing or transcriptional regulation by
multiplexed gRNAs, predictive algorithms and computational
tools to design optimal gRNAs will prove crucial. Considerable
progress has been made in designing computational tools and
incorporating biological factors into de novo predictions of gRNA
efficiencies, but further developments are required (Box 1).
Orthogonal and inducible CRISPR–Cas technologies
As the number of gRNAs in a biological system increases,
researchers must implement control mechanisms to limit cross
talk between components and minimize off-target effects. Addi-
tional control over CRISPR–Cas can be implemented by
expressing multiple Cas orthologs in vivo, by creating inducible
systems wherein CRISPR–Cas components are expressed only
when they are needed, or via direct engineering of gRNAs (which
has been reviewed elsewhere)54.
Cas orthologs from different organisms each recognize a
slightly different gRNA structure, enabling orthogonal assembly
of ribonucleoprotein complexes. For Cas9, the nexus and hair-
pin of an sgRNA dictates which Cas9 ortholog they associate
with (e.g., SpCas9 from S. pyogenes vs. SaCas9 from S. aureus),
and swapping the nexus and hairpin regions alters which Cas
ortholog is recognized55. Promiscuous fusion gRNAs (fgRNAs),
which can associate with either Cas9 or Cas12a, have also been
developed56. In yeast, Cas enzymes for gene editing, CRISPRa
and CRISPRi have been expressed simultaneously in vivo, and
functioned orthogonally simply by expressing three different
gRNA architectures15.
Other strategies to minimize cross talk have utilized truncated
gRNAs which, in some cases, are unable to mediate cleavage of
target DNA, but can still recognize a genetic locus and mediate
transcriptional regulation7. Normal length gRNAs, on the other
hand, preferentially mediate cleavage of target DNA. By encoding
both short and long gRNAs from a single array, and co-
expressing both active and nuclease-null versions of Cas12a in
human cells, simultaneous gene editing and transcriptional reg-
ulation of 15 genes was achieved in tandem24.
Expression of dCas9 is toxic in bacteria, and expression of
additional dCas9 enzymes could further burden cells8,57. To
overcome this in E. coli, scaffold RNAs (scRNAs), which are
modified sgRNAs that encode both a target sequence and an RNA
hairpin that recruits specific effector proteins, were used for
bifunctional CRISPRi/CRISPRa with a single dCas enzyme9. This
strategy, in which orthogonal scRNAs are used in lieu of
expressing multiple different endonucleases, is also applicable in
yeast and human cells58. T7 polymerase, a single-subunit enzyme
Box 1 | Computational methods for designing sgRNAs
For efficient editing or transcriptional regulation, well-designed gRNAs, with high efficiencies (on-target scores) and specificities (off-target scores), are
required. This need is further compounded in the context of multiplexing, where multiple gRNAs edit or regulate numerous genetic loci in tandem.
Target sites are easily identified by bioinformatic tools, whereby a genome is scanned to find a 18–23 bp region adjacent to a PAM site. It is much more
challenging, however, to predict the on- and off-target score of each gRNA de novo. The on-target score of a gRNA is a measure of its ability to bind to
its specific target site, while off-target scores predict the likelihood that a gRNA will bind other, undesired positions in the genome121.
On-target scores are often generated by transforming large libraries of gRNAs, together with a specific Cas protein, into cells and then reading out the
indels via genome-wide profiling methods, such as Digenome-seq, GUIDE-seq and BLESS122–124. Genome-wide libraries of gRNAs have been developed
and tested in many organisms, including rats, mice, human cells, S. cerevisiae, and E. coli125–129.
Off-target rules can be generated simply by scanning the genome for similar target sites or, like on-target scores, can be based on genome-wide
screens. Most predictive models for off-target scores incorporate the position, number, and identity of mismatches between the spacer and DNA at
non-target positions125,130.
Many algorithms for estimating gRNA efficiencies now extend beyond datasets comprising indel cutting efficiencies, and additionally incorporate
chromatin, position, gRNA stability, Cas9 loading and sequence features of the genetic locus into the predictive model131,132. Biophysical models for
CRISPR–Cas9 activity have also been developed, which leverage statistical mechanics and kinetics to model each step and factor in Cas9-mediated
cleavage, including ribonucleoprotein formation and DNA supercoiling133. There are also online databases (notably WeReview: CRISPR Tools) that
provide updated lists of bioinformatics tools available for CRISPR–Cas experiments134.
A variety of gRNA design tools are either freely available online or are integrated into DNA analysis software, such as Benchling or Geneious. Generally,
these tools allow users to choose from hundreds of reference genomes, select PAM sites, target site, and receive predictions for gRNA efficiencies
(based on multiple scoring algorithms), the likelihood of observing off-target effects and, in some cases, the percentage of clones that will carry frame
shifts135. Many of these design tools have been reviewed elsewhere136.
The efficiency and specificity of any given gRNA is intimately dependent upon its context; expression levels, the organism in which it is expressed, the
Cas enzyme, accessibility of the genetic locus and other factors all affect function. This context-dependency necessitates additional experimental
datasets and computational algorithms for more precisely predicting gRNA efficiencies, especially for multiplexed applications101,132.
Recently, tools to optimize gRNAs based on less used endonucleases, particularly Cas12a and certain Cas9 orthologs, have also been developed, many
of which use deep learning frameworks to predict activity based on large training sets137–139. These studies are essential because gRNAs behave
differently when complexed with different endonucleases, and predictive algorithms should therefore be based on experimental data collected within a
desired context.
Unfortunately, the bulk of algorithms available are still based on editing efficiencies, even though gRNAs for transcriptional regulation require vastly
different targeting rules. Current gRNA design tools for CRISPRi and CRISPRa, such as CHOPCHOP v3, integrate positional factors into design rules,
while a machine learning-based algorithm additionally incorporates nucleosome positioning, sequence features and other factors to predict highly active
gRNAs130,131.
Recently, a computational tool to regulate many genes simultaneously in prokaryotes has been developed. This tool designs gRNAs with orthogonal
Cas9 handles that can target between 1 and 20 input sequences48. Future computational tools made specifically for gRNA arrays should incorporate
retroactive effects, gRNA; gRNA interactions, and many other factors. We are hopeful that the acquisition of additional, large-scale datasets, particularly
those tested with varying Cas enzymes and in diverse organisms, will elucidate the underlying design principles of gRNAs regardless of the context in
which they are expressed. The ability to predict gRNA efficiencies based solely on its expression level, the Cas enzyme used, and the context of a
genetic locus—including nucleosome positioning, target position relative to transcription start site, and other factors—may be possible in the future, but
will require careful measurements and well-validated datasets (Box 2).
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that recognizes a short, 17 bp promoter, has also been used for
orthogonal expression of sgRNAs in different yeasts, including S.
cerevisiae and Yarrowia lipolytica59.
Cas enzymes can also be turned “on” selectively, either to limit
toxicity or to enhance programmability, by linking endonuclease
expression to light- or chemical-inducible promoters9,60. In the
near future, we suspect that strategies leveraging anti-CRISPR
proteins to rapidly turn “off” endonuclease functions will also be
deployed61. Other strategies to control CRISPR–Cas activity rely
on modifications to the structure of sgRNAs; conditional gRNAs
are either constitutively active and turned “off” by RNA termi-
nator switches, or are constitutively inactive and turned “on” by
an RNA trigger62. This strategy has been demonstrated in both
bacteria and human cells, enabling programmable CRISPR–Cas
activity in vivo.
sgRNA behaviors can also be controlled by appending indu-
cible, spacer-blocking hairpins to sgRNAs, which abrogates their
ability to transcriptionally regulate target genes until they are
turned “on” by a genetically encoded or exogenous signal63.
Another method for inducible activation is to flank each sgRNA
with microRNA-complementary binding sites64. In the presence
of cognate microRNAs or short interfering RNAs (siRNA),
functional sgRNAs are produced via Argonaute2 (Ago2)-medi-
ated cleavage, an enzyme that cleaves mRNAs with sequences
complementary to a microRNA or siRNA65. Recently, “switch-
able” Cas12a gRNAs with 5′ extensions have also been reported in
bacterial cells, which are activated in response to a single-
stranded RNA trigger, including full length mRNAs66.
With strategies to minimize cross talk between orthogonal Cas
enzymes and gRNAs facilitating the implementation of multi-
plexed CRISPR applications, a range of biological and engineering
applications have become accessible.
Applications enhanced by multiplexed CRISPR technologies
Multiplexed CRISPR–Cas technologies have advanced numerous
applications in basic science, synthetic biology, and biotechnol-
ogy. Though there are too many applications to discuss here, we
highlight those topics which specifically benefit from multiplexed
strategies, such as combinatorial mapping of genotype-to-phe-
notype, rapid strain and metabolic engineering, multi-input bio-
sensing, multi-event recording in living cells, and multi-layered,
digital logic circuits (Fig. 4).
CRISPR-based genetic circuits
One of the main objectives of synthetic biology is to construct
genetic circuits that can control cellular behavior, but there have
been serious challenges to this endeavor. A lack of well-char-
acterized, orthogonal parts means that it is difficult to scale cir-
cuits and connect many individual regulators together8. The
programmability of RNA:DNA base pairing, enabled by
CRISPR–Cas systems, has facilitated the construction of large
logic circuits with many orthogonal regulators. In yeast, 20
gRNA–promoter pairs have been shown to operate orthogonally
and, in bacteria, at least 5 pairs have been demonstrated14,16.
Numerous studies have implemented multiplexed, CRISPR-
based logic in human, yeast, and bacterial cells (Fig. 4a)14,16,67.
For example, a central processing unit consisting of dCas9 fused
to a transcriptional repressor has been used, together with mul-
tiple sgRNAs, to construct layered NOR gates in E. coli and
numerous bitwise operators in human cells14,67. A NOR gate is a
type of Boolean operator that produces an output signal only if
both inputs are negative. A CRISPR-based NOR gate, therefore,
constitutively produces an output signal (e.g., GFP or a gRNA),
but is turned off when a gRNA binds to its promoter and
represses transcription. In yeast, dCas9-based NOR gates with up
to seven layers have been constructed16. In E. coli, NOT and NOR
gates with up to five sgRNAs have also been coupled to native
regulatory networks, where the output of a logic circuit is used
to control a cellular phenotype, such as sugar utilization or
chemotaxis14.
Such logic circuits have also been used to detect specific cell
types and produce therapeutic payloads in response. In bladder
cancer cells, for example, simultaneous activation of two cell type-
specific promoters were linked to the output of different effector
genes that could trigger cell death, arrest growth, or impair cell
motility68. CRISPR-based logic circuits offer a programmable
means to detect different biomarkers as inputs—which makes
them a foundational tool for the assembly of more complex
biosensors—and can actuate therapeutic payloads in response to
such inputs67.
Multi-input biosensing and diagnostics
Cas enzymes can be programmed to detect and cleave specified
RNA or DNA sequences, making them a logical choice for bio-
sensor development (Fig. 4b)69. Multiplexed strategies are again
advantageous because the addition of gRNAs enables numerous
pathogens to be detected in a single assay or multiple markers to
be analyzed for a single pathogen, thus reducing costs, improving
accuracy, and broadening diagnostic utility.
In vitro biosensors for viral and bacterial pathogens often rely
on Cas13a (previously known as C2c2), which is a programmable
RNA-guided RNase, and Cas12a70. Importantly, there are many
orthologs of Cas12a and Cas13a71. Following DNA or RNA
amplification72,73, Cas13a and Cas12a in complex with a gRNA
recognize a target RNA or DNA, respectively. Upon target
recognition, both enzymes nonspecifically cleave nearby RNAs or
ssDNAs, respectively, in a process known as collateral cleavage74.
By adding single-stranded RNA or DNA fused to fluorescent
probes, this collateral cleavage mechanism can be exploited to
conditionally produce a visible output only after formation of
Cas12a/Cas13a complex hybridization with the target sequence
and cleavage of the fluorescent probes, thus releasing the output
signal72,73. By expressing multiple Cas13a and Cas12 orthologs
and tuning the single-stranded linkers in these fluorescent probes,
multiple reporter outputs can function orthogonally, increasing
the number of pathogens that can be detected in a single assay73.
In vitro DNA-based biosensors have also enabled detection of
pathogens, like Mycobacterium tuberculosis, by fusing two sepa-
rate dCas9 enzymes to split halves of an output signal, such as
luciferase. Each dCas9-fusion protein is programmed by sgRNAs
that recognize proximal positions on an M. tuberculosis target
sequence. Luminescence is generated when each dCas9 split-pair
recognizes, and binds, to the DNA target, thus bringing the
luciferase halves together75.
Combinatorial mapping of genotype to phenotype
For decades, researchers have deleted genes and studied their
phenotypic impact in a range of organisms, shaping our under-
standing of how the genome encodes information and regulates
behavior. Unfortunately, rapid methods to delineate how com-
binations of genes contribute to a phenotype have been sorely
limiting. CRISPR multiplexing can be used to probe these com-
binatorial, genotype-to-phenotype questions by perturbing com-
binations of genes in tandem, wherein sequence-based readouts
of a genetic barcode (each mapped to a specific sgRNA sequence)
is used to determine which cells received which sgRNAs (Fig. 4c).
To systematically dissect gene interactions responsible for
ovarian cancer cell growth, one study used a library of 23,409
barcoded, gRNA pairs targeting fifty different genes encoding
epigenetic regulators, based on known ovarian cancer drug
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targets76. Each gRNA was produced from an individual promoter,
and lentiviral transduction of each gRNA pair, followed by serial
passaging of the ovarian cancer cells and sequencing of barcode
frequencies over time, elucidated pairs of gRNAs that inhibit
cancer growth.
Similar combinatorial gRNA libraries have also been used with
CRISPRi to explore how combinations of enhancers regulate the
expression of estradiol-responsive genes and to map enhancer-
gene pairs in human cells77,78. In the latter example, approxi-
mately 28 CRISPRi perturbations were made per cell using len-
tiviral transductions, and transcriptional repression of genetic loci
was read out by single-cell RNA sequencing. By transducing
random, triple combinations of sgRNAs, each expressed from an
individual promoter, combinatorial perturbations by gRNAs were
also used to determine genes involved in the unfolded protein
response (a cellular stress response pathway) in human cells by
screening for cells with perturbed homeostasis of the endoplasmic
reticulum79.
Multiplexed cellular recording
CRISPR-based bacterial adaptive immunity is a molecular
recorder, whereby cells record past infections as spacers in the
genome. CRISPR technologies have enabled the construction of
DNA-based cellular recording devices that can provide temporal
and spatial information for a milieu of biological questions
(Fig. 4d)80.
In practice, CRISPR-based DNA memory devices require three
elements: sensing of a signal, the writing of that signal into DNA,
and the readout of the modified DNA (typically via sequencing of
the loci) to reconstruct the information80. The first element,
sensing, relies on protein sensors that transduce signals into the
expression of a gRNA, which then serves as the ‘writing’ element
to record the presence of that signal at a specified locus.
Multiplexed gRNAs can be used to record multiple input sig-
nals, including their duration, strength, and the order in which
they appear81. CAMERA (CRISPR-mediated analog multi-event
recording apparatus), for example, can simultaneously sense and
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Fig. 4 Applications of multiplexed CRISPR–Cas technologies. a Multiple gRNAs can be expressed, together with dCas9, to build complex logic circuits,
including wired NOR gates, in which upstream gRNAs regulate the expression of downstream sgRNAs. Logic circuits can be used to produce a simple
output signal, like GFP, or can be interfaced into cellular pathways to control phenotypes or behaviors. b Cas13a orthologs can be used to detect multiple
viral pathogens at once. The viruses are lysed, their genomes are amplified, and the amplified RNA is then used as the input for Cas13a-based biosensors.
Upon recognition of an RNA target, Cas13a collaterally cleaves nearby transcripts, a characteristic that can be exploited to release orthogonal, fluorescent
outputs from ssRNA reporters. cMultiplexed gRNAs enable combinatorial mapping of genotype to phenotype. Pairs of gRNAs, each with a unique barcode,
are programmed to target different genes involved in a known pathway or cellular process. These gRNA:barcode pairs are transformed into Cas9-
expressing cells, and the barcodes of each cell in a population are sequenced to determine which gRNA pair each cell received. By measuring the frequency
of the barcodes over multiple conditions, combinations of genes that modulate a given phenotype can be inferred. dMulti-event recording enables multiple
signals to be detected and recorded in the genome of living cells. One gRNA is used to “write” each detected signal. Event recorders commonly use base
editors and gRNAs that target a pre-defined locus, and recordings can be read out by sequencing the targeted loci. e Multiplexed CRISPR–Cas enables
specific genomic rearrangements or modifications, including indels (which are produced by error-prone, non-homologous end joining) and insertions (via
homology-directed repair, where donor DNA contains homology arms to the double-strand break), for rapid strain engineering. f Multiplexed CRISPR–Cas
technologies can be used to perturb numerous parts of a pathway simultaneously, thus redirecting flux and enhancing the production of a desired
compound. CRISPRi, CRISPRa, and editing of DNA can be achieved simultaneously, simply by expressing orthogonal dCas:gRNA pairs (one for activation
and another for repression), together with Cas12a or Cas9 for editing.
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record exposure to two antibiotic signals in tandem by using a
base editor to convert C•G → T•A at specified loci. Further
sgRNA multiplexing may enable the sensing and recording of
additional signals. Other multiplexed recorders have also been
developed, which can be ‘layered’ and interconnected, like genetic
circuits, to both record and control molecular events in both
bacterial and eukaryotic cells82.
Genome, strain, and metabolic engineering
Multiplexed CRISPR–Cas technologies have been applied, with
incredible success, for both rapid genome editing and for the
transcriptional rewiring of metabolic pathways (Fig. 4e). CRISPR
multiplexing has enabled genome editing strategies that would
be difficult, or impossible, to achieve with traditional genetic
engineering methods. Programmable, large-scale genome rear-
rangement and assembly in E. coli was recently performed by
expressing six gRNAs; two that cut the genome and four others
that cut a bacterial artificial chromosome (BAC), enabling large
(greater than 100 kb) genome fragments to be rearranged at
will83. A similar CRISPR multiplexing strategy was also used to
build a chemically synthesized, 61-codon E. coli genome, where
DNA megachunks were placed onto BACs and incorporated into
the genome via multiplexed cleavage of dsDNA and lambda red
recombination84. Genomic truncations can occur as a result of
double-strand breaks, however, which may mitigate the utility of
Cas9 for implementing specific mutations85. For precision
applications requiring single nucleotide resolution, nickases and
base editors, which do not induce dsDNA breaks, are preferred.
Multiplexed genome editing has also been used to create ani-
mal models for studying combinatorial genotype-to-phenotype
relationships and to engineer biallelic mutations of multiple
genetic loci at once36,86. In the largest example of multiplexing to
date, 62 gRNAs were transduced into pig cells in tandem to
remove all copies of porcine endogenous retroviruses, with 8% of
cells having 60–100% knockout rates87.
In metabolic engineering, more fine-tuned approaches to
gene modulation are demanded, as the flux through a pathway
must be tightly regulated to enhance production of a desired
chemical without impinging upon growth (Fig. 4f). Multiplexed
CRISPR–Cas technologies are frequently used to simultaneously
activate and repress multiple genes at once, an approach that has
been used to enhance cellobiose consumption in Yarrowia lipo-
lytica, isoprenoid production in S. cerevisiae, and n-butanol and
terpenoid production in E. coli88–91. More recently, a study
increased succinic acid production approximately 150-fold in E.
coli by co-expressing an inducible dCas9 with 20 sgRNAs to
knockdown 6 genes48. Inducible dCas9 or gRNAs enable control
over the timing and magnitude of metabolic pathway regulation,
and can be used to implement growth decoupling mechanisms
in vivo, whereby “growth” and “bioproduction” states are toggled
at will to enhance fermentation yields once a population of cells
reach a desired biomass92. Our group has also previously used
xylose-inducible, multiplexed CRISPRi with three gRNAs (tar-
geting N-Acetylglucosamine synthesis, glycolysis and pepti-
doglycan synthesis) to engineer a GlcNac overproducer Bacillus
subtilis that can simultaneously co-utilize glucose and xylose, a
feat not possible by many wild-type bacteria because of carbon
catabolite repression93.
Insights and challenges of multiplexed crispr technologies
Despite the utility of multiplexed CRISPR technologies, serious
biological and technical challenges remain. Perhaps most
important, from an engineering standpoint, are the current dif-
ficulties in creating long arrays of gRNAs, and in predicting how
these gRNAs will behave in living cells. The technical challenge of
array assembly is rapidly being surmounted, thanks to better
DNA synthesis chemistry and the development of orthogonal
Cas9 handles that minimize repetitive sequences in sgRNA con-
structs, which were previously discussed48.
While we envision that current challenges in DNA synthesis
and gRNA design, for example, will be overcome in the near
future, other challenges will take longer to solve. One prominent
problem with using CRISPR multiplexing to cut multiple genetic
loci at once is the emergence of undesired chromosomal rear-
rangements. Fortunately, some studies have used paired sets of
gRNAs to make specific cuts on chromosomes and then analyze
the resulting rearrangements, and indicate that these large-scale
rearrangements may be predictable in advance94.
Another serious challenge is that, as the number of gRNAs in a
cell scales, they must compete for a dwindling ‘pool’ of endo-
nucleases. This competition, in turn, alters the efficiency of every
gRNA, an effect called retroactivity8. While synthetic biologists
strive for modularity by combining many individually char-
acterized genetic parts together, the interconnections between
these parts often result in unpredictable outputs—this is espe-
cially pertinent for CRISPR–Cas multiplexing95. Retroactivity also
makes it difficult to predict gRNA efficiency from sequence,
another major obstacle for scaling multiplexed systems (Box 1).
Some studies have attempted to quantify the retroactive effects
of multiplexed sgRNAs, and have demonstrated that titration of
dCas9 with an increasing number of sgRNAs leads to predictable
decreases in gRNA efficiencies96. In E. coli, sgRNAs for CRISPRi
exhibited less than 10-fold repression once 7 or more sgRNAs
were expressed (down from ~60-fold repression exhibited by the
first sgRNA)8. A simple, ordinary differential equation model
suggests that dCas9 bottlenecks cause CRISPRi target repression
to drop off by roughly 1/N, where N is the number of sgRNAs
expressed96. This effect was partly ameliorated in bacteria by
using a dCas9-repressor fusion that recognizes a specific operator
sequence and exhibits a lower toxicity, though this reduces the
flexibility of DNA targeting8. dCas9 bottlenecking could possibly
be mitigated by using conditional gRNAs, which are selectively
triggered as needed in vivo62.
Cas9:gRNA complexes can recognize and bind genetic loci with
as little as 5-nt of homology with the spacer, leading to off-target
binding. Scaling the number of gRNAs within a cell enhances
these off-target effects. Many sophisticated, genome-wide screens
have assessed how parameters in gRNA spacer sequences,
mismatches, and even the targeting of non-coding genes, can
enhance off-target effects and deleteriously impact fitness for
Cas9-mediated editing, CRISPRi and CRISPRa97–99. Fortunately,
there are numerous strategies to mitigate off-target binding,
including direct modification of the gRNA by shortening the
spacer or truncation of one end of the tracrRNA element100,101.
Other strategies employ mutant Cas9 endonucleases that function
as nickases, with paired sets of gRNAs, which have been shown to
reduce off-target effects as much as 1500-fold in certain cell lines
compared to wild-type Cas9102. dCas9 can also be fused to FokI
nuclease domains, which significantly improves target-specific
editing compared to wild-type Cas9103,104. The recent develop-
ment of search-and-replace genome editing, wherein nuclease-
null Cas9 nickase is fused to an engineered reverse transcriptase,
also enables DNA editing (insertions and all 12 types of base-to-
base conversions) without double-strand breaks, and reduces off-
target effects compared to wild-type Cas9105.
When working with gRNA-expressing arrays, one must
account for context-dependent effects (Box 2). In some Csy4-
processed arrays, for example, internally positioned gRNAs have
lower expression compared to those placed on the ends of
arrays34. gRNA arrays processed by Cas12a also vary drastically
in mature RNA abundance based on their initial spatial position,
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15053-x REVIEW ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1281 | https://doi.org/10.1038/s41467-020-15053-x | www.nature.com/naturecommunications 9
likely due to the formation of stable, imperfect hairpins bridging
spacer sequences23,24. In both cases, spatial effects can diminish
gRNA expression and, in turn, efficiency.
Even in cases where numerous high-efficiency gRNAs are
expressed, we still do not have a clear understanding of the limits
for gRNA multiplexing in vivo. Despite our belief that hundreds
of gRNAs could be expressed at once, it is unclear whether they
would be effective due to increased competition for Cas enzymes.
The processing efficiency of certain methods, including Csy4,
ribozymes, and tRNA, will play a crucial role in determining the
theoretical gRNA ceiling, and strategies to both create and pro-
cess long arrays should be optimized in future studies.
Future directions
CRISPR multiplexing offers a powerful approach to answer both
fundamental and applied research questions. But despite the
abundance of tools and techniques available, serious challenges
remain. While some organisms encode 400 or more gRNAs
within their CRISPR locus, engineered strategies have thus far
been limited to arrays with just 25 gRNAs. However, it is feasible
that existing methods of gRNA array assembly, as outlined in this
review, will enable the in vivo expression of much longer arrays.
Additionally, native CRISPR systems employ many Cas enzymes
in tandem, each with specified functions, to transcribe, process,
and utilize these gRNAs—we envision that the same could soon
be accomplished with engineered organisms.
We suspect that future developments in the CRISPR multi-
plexing field will be limited not by a lack of CRISPR–Cas-based
tools, but rather by deficiencies in our mechanistic understanding
of how things like Cas toxicity, on- and off-target effects and
orthogonality between CRISPR components actually operate
in vivo106. Ongoing advancements in basic biology and genomics,
computation, and chemistry will ameliorate some of the current
bottlenecks in gRNA multiplexing. Chemistries for DNA
synthesis have significantly improved in recent years, and some
companies are now able to synthesize long, highly repetitive
sequences, which will ease current technical challenges in pro-
ducing arrays24. In addition, cleaner datasets of gene targeting
efficiency and gRNA abundance produced from standardized
next-generation sequencing protocols could enable highly pre-
dictive computational models for sgRNAs embedded within
arrays, accounting for processing efficiency, spatial context of the
genetic loci, and other factors (Box 2). In the future, a deeper,
mechanistic understanding of gRNA:DNA binding may even
enable highly precise modulation of gene expression, rather than
the general up- and downregulation that is common today.
Multiplexed gRNAs with “non-canonical” Cas enzymes, espe-
cially Cas13a, may enable all-in-one diagnostics for specific
classes of viral and bacterial pathogens107. As the number of
gRNAs that can be expressed in vivo expands, we also envision
minimal cells that operate and respond to environmental cues via
entirely synthetic, programmable, transcriptional regulatory net-
works67. The ability to rewire the metabolisms and genome
regulatory networks of living cells could even help shift the planet
away from a petroleum-based economy. CRISPR multiplexing
will also serve as a crucial tool to probe deep questions in fun-
damental biology, particularly as our ability to precisely control
transcription improves108.
The pace of research in CRISPR multiplexing has been
astonishing. But to continue advancing in our ability to engineer
living organisms, we will require rigorous, quantitative datasets
that accurately capture the milieu of factors governing the effi-
ciency of any engineered CRISPR–Cas technology. For example,
scientists could study how parameters such as gRNA abundance
impinge on gene expression using quantitative RNA-seq or
quantify how specific gRNAs used with CRISPRi and CRISPRa
alter the abundance of proteins using mass spectrometry (Box 2).
With biologists, chemists and engineers working together, and
quantitative measurements in hand, we may soon have the
unprecedented ability to control, rewire, and program genomes in
a totally predictable manner.
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